Symbols / TRIB $0.62 +2.52% Trinity Biotech plc
TRIB Chart
About
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to aggressive forms of the disease. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 11.70M |
| Enterprise Value | 340.85M | Income | -36.28M | Sales | 48.57M |
| Book/sh | -2.93 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 401 | IPO | — |
| P/E | — | Forward P/E | -0.60 | PEG | — |
| P/S | 0.24 | P/B | -0.21 | P/C | — |
| EV/EBITDA | -24.30 | EV/Sales | 7.02 | Quick Ratio | 0.47 |
| Current Ratio | 1.03 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.60 | EPS next Y | -1.03 | EPS Growth | — |
| Revenue Growth | -5.50% | Earnings | 2025-07-01 09:00 | ROA | -9.46% |
| ROE | — | ROIC | — | Gross Margin | 36.78% |
| Oper. Margin | -3.56% | Profit Margin | -75.88% | Shs Outstand | 18.90M |
| Shs Float | 293.05M | Short Float | 1.91% | Short Ratio | 0.95 |
| Short Interest | — | 52W High | 3.44 | 52W Low | 0.48 |
| Beta | 0.79 | Avg Volume | 252.28K | Volume | 84.89K |
| Target Price | — | Recom | None | Prev Close | $0.60 |
| Price | $0.62 | Change | 2.52% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- TRINITY BIOTECH Q4 2025 Earnings Preview: Recent $TRIB Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 01 Apr 2026 21
- TRIB SEC Filings - Trinity Biotech Plc 10-K, 10-Q, 8-K Forms - Stock Titan Sun, 05 Apr 2026 11
- SUNDAY, APRIL 5, 2026 Ad - Boscov's - Tribune-Review - TribLIVE.com Sun, 05 Apr 2026 19
- TRIB Apr 2026 2.500 call (TRIB260417C00002500) Interactive Stock Chart - Yahoo! Finance Canada Wed, 01 Apr 2026 02
- Stocks swing through another shaky day as oil prices keep climbing - TribLIVE.com Mon, 30 Mar 2026 22
- Trinity Biotech (TRIB) director John Paul Tivnan files Form 3 with no trades - Stock Titan Fri, 03 Apr 2026 12
- (TRIB.KL) stock price, news, quote and history - Yahoo Finance UK Sat, 28 Mar 2026 22
- Pitt WR Deuce Spann raises NFL Draft stock with impressive pro day performance - TribLIVE.com Fri, 27 Mar 2026 14
- Interim CFO Paul Murphy listed as insider at Trinity Biotech (TRIB) - Stock Titan Fri, 03 Apr 2026 12
- John Dorfman: My Nasdaq stock picks have averaged 17.9% return - TribLIVE.com Wed, 18 Mar 2026 07
- Director John Gillard details ADS option stakes in Trinity Biotech (TRIB) - Stock Titan Fri, 03 Apr 2026 12
- Trinity Biotech (TRIB) director discloses $2.80 ADS option positions - Stock Titan Fri, 03 Apr 2026 12
- John Dorfman: Defense stocks could explode upward again - TribLIVE.com ue, 24 Mar 2026 20
- Brazil adopts world’s only IFCC Gold HbA1c diabetes system - Stock Titan hu, 12 Mar 2026 07
- A urine prostate cancer test hit 85% accuracy in a 750-patient study - Stock Titan Mon, 23 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
61.55
+8.31%
|
56.83
-9.10%
|
62.52
-22.96%
|
81.15
|
| Operating Revenue |
|
61.55
+8.31%
|
56.83
-9.10%
|
62.52
-22.96%
|
81.15
|
| Cost Of Revenue |
|
40.11
+7.31%
|
37.38
-17.39%
|
45.25
-5.12%
|
47.70
|
| Reconciled Cost Of Revenue |
|
40.11
+7.31%
|
37.38
-17.39%
|
45.25
-5.12%
|
47.70
|
| Gross Profit |
|
21.44
+10.24%
|
19.45
+12.64%
|
17.27
-48.38%
|
33.45
|
| Operating Expense |
|
36.93
+4.35%
|
35.39
+14.98%
|
30.78
+14.00%
|
27.00
|
| Research And Development |
|
4.54
+3.75%
|
4.38
+5.82%
|
4.14
-7.98%
|
4.50
|
| Selling General And Administration |
|
28.82
-7.50%
|
31.15
+15.45%
|
26.98
+19.91%
|
22.50
|
| General And Administrative Expense |
|
—
|
—
|
—
|
24.68
|
| Other Gand A |
|
—
|
—
|
—
|
24.68
|
| Other Operating Expenses |
|
3.57
+2689.86%
|
-0.14
+59.41%
|
-0.34
+92.72%
|
-4.67
|
| Total Expenses |
|
77.05
+5.87%
|
72.78
-4.29%
|
76.03
+1.79%
|
74.69
|
| Operating Income |
|
-15.49
+2.84%
|
-15.94
-17.98%
|
-13.51
-309.37%
|
6.45
|
| Total Operating Income As Reported |
|
-21.16
+21.74%
|
-27.05
-39.77%
|
-19.35
-591.34%
|
3.94
|
| EBITDA |
|
-16.91
+32.39%
|
-25.00
+16.42%
|
-29.91
-577.34%
|
6.27
|
| Normalized EBITDA |
|
-13.01
-0.15%
|
-12.99
-18.67%
|
-10.95
-224.59%
|
8.79
|
| Reconciled Depreciation |
|
1.86
+4.95%
|
1.78
-23.83%
|
2.33
-14.98%
|
2.74
|
| EBIT |
|
-18.77
+29.91%
|
-26.78
+16.96%
|
-32.25
-1015.36%
|
3.52
|
| Total Unusual Items |
|
-3.89
+67.58%
|
-12.01
+36.68%
|
-18.97
-652.66%
|
-2.52
|
| Total Unusual Items Excluding Goodwill |
|
-3.89
+67.58%
|
-12.01
+36.68%
|
-18.97
-652.66%
|
-2.52
|
| Special Income Charges |
|
-3.89
+67.58%
|
-12.01
-29.29%
|
-9.29
-268.61%
|
-2.52
|
| Other Special Charges |
|
-1.70
-287.29%
|
0.91
-73.77%
|
3.45
+177.98%
|
-4.42
|
| Impairment Of Capital Assets |
|
2.21
-77.01%
|
9.61
+79.30%
|
5.36
-15.78%
|
6.36
|
| Restructuring And Mergern Acquisition |
|
4.18
|
0.00
|
0.00
|
—
|
| Write Off |
|
-0.80
-153.33%
|
1.50
+211.20%
|
0.48
-17.32%
|
0.58
|
| Net Income |
|
-31.79
-32.35%
|
-24.02
+41.43%
|
-41.01
-4786.74%
|
0.88
|
| Pretax Income |
|
-30.73
+16.78%
|
-36.93
+15.65%
|
-43.78
-2175.47%
|
-1.92
|
| Net Non Operating Interest Income Expense |
|
-13.13
-46.28%
|
-8.98
+20.58%
|
-11.30
-92.82%
|
-5.86
|
| Interest Expense Non Operating |
|
11.96
+17.86%
|
10.15
-12.00%
|
11.53
+111.71%
|
5.45
|
| Net Interest Income |
|
-13.13
-46.28%
|
-8.98
+20.58%
|
-11.30
-92.82%
|
-5.86
|
| Interest Expense |
|
11.96
+17.86%
|
10.15
-12.00%
|
11.53
+111.71%
|
5.45
|
| Interest Income Non Operating |
|
0.00
-100.00%
|
1.17
+286.47%
|
0.30
+10000.00%
|
0.00
|
| Interest Income |
|
0.00
-100.00%
|
1.17
+286.47%
|
0.30
+10000.00%
|
0.00
|
| Other Income Expense |
|
-3.89
+67.57%
|
-12.01
+36.69%
|
-18.96
-653.74%
|
-2.52
|
| Other Non Operating Income Expenses |
|
—
|
0.00
+0.00%
|
0.00
-25.00%
|
0.00
|
| Gain On Sale Of Security |
|
—
|
—
|
-9.68
|
—
|
| Gain On Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Tax Provision |
|
0.49
+923.73%
|
-0.06
+69.59%
|
-0.19
-162.16%
|
-0.07
|
| Tax Rate For Calcs |
|
0.00
+7722.28%
|
0.00
-63.94%
|
0.00
-88.48%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.49
-2436.62%
|
-0.02
+77.17%
|
-0.08
+13.28%
|
-0.10
|
| Net Income Including Noncontrolling Interests |
|
-31.79
-32.35%
|
-24.02
+41.43%
|
-41.01
-4786.74%
|
0.88
|
| Net Income From Continuing Operation Net Minority Interest |
|
-31.22
+15.33%
|
-36.87
+15.41%
|
-43.59
-2256.00%
|
-1.85
|
| Net Income From Continuing And Discontinued Operation |
|
-31.79
-32.35%
|
-24.02
+41.43%
|
-41.01
-4786.74%
|
0.88
|
| Net Income Continuous Operations |
|
-31.22
+15.33%
|
-36.87
+15.41%
|
-43.59
-2256.00%
|
-1.85
|
| Net Income Discontinuous Operations |
|
-0.57
-104.46%
|
12.85
+398.64%
|
2.58
-5.43%
|
2.73
|
| Normalized Income |
|
-27.81
-11.78%
|
-24.88
-0.70%
|
-24.70
-4410.60%
|
0.57
|
| Net Income Common Stockholders |
|
-31.79
-32.35%
|
-24.02
+41.43%
|
-41.01
-4786.74%
|
0.88
|
| Diluted EPS |
|
-1.80
+43.75%
|
-3.20
+47.37%
|
-6.08
-3140.00%
|
0.20
|
| Basic EPS |
|
-1.80
+43.75%
|
-3.20
+47.37%
|
-6.08
-3140.00%
|
0.20
|
| Basic Average Shares |
|
17.96
+134.61%
|
7.65
+13.46%
|
6.75
+61.40%
|
4.18
|
| Diluted Average Shares |
|
20.20
+127.00%
|
8.90
+31.92%
|
6.75
+26.68%
|
5.33
|
| Diluted NI Availto Com Stockholders |
|
-31.79
-32.35%
|
-24.02
+41.43%
|
-41.01
-4786.74%
|
0.88
|
| Total Other Finance Cost |
|
1.17
+200.09%
|
-1.17
-1682.43%
|
0.07
-82.30%
|
0.42
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
103.29
+73.79%
|
59.44
-35.47%
|
92.10
-22.53%
|
118.89
|
| Current Assets |
|
41.12
+5.34%
|
39.04
-16.34%
|
46.67
-35.80%
|
72.69
|
| Cash Cash Equivalents And Short Term Investments |
|
5.17
+39.99%
|
3.69
-43.89%
|
6.58
-74.61%
|
25.91
|
| Cash And Cash Equivalents |
|
5.17
+39.99%
|
3.69
-43.89%
|
6.58
-74.61%
|
25.91
|
| Cash Equivalents |
|
—
|
—
|
0.00
-100.00%
|
3.12
|
| Cash Financial |
|
5.17
+39.99%
|
3.69
-43.89%
|
6.58
-71.14%
|
22.79
|
| Receivables |
|
14.60
+9.14%
|
13.38
-14.52%
|
15.65
-0.36%
|
15.71
|
| Accounts Receivable |
|
13.42
+25.41%
|
10.70
-15.22%
|
12.62
-5.05%
|
13.29
|
| Gross Accounts Receivable |
|
15.70
+20.58%
|
13.02
-14.94%
|
15.31
-5.94%
|
16.28
|
| Allowance For Doubtful Accounts Receivable |
|
-2.29
+1.64%
|
-2.32
+13.64%
|
-2.69
+9.88%
|
-2.99
|
| Other Receivables |
|
0.63
-44.13%
|
1.12
-2.94%
|
1.16
+31.44%
|
0.88
|
| Taxes Receivable |
|
0.56
-64.08%
|
1.56
-16.94%
|
1.88
+21.96%
|
1.54
|
| Inventory |
|
19.37
-2.80%
|
19.93
-11.42%
|
22.50
-22.73%
|
29.12
|
| Raw Materials |
|
10.03
-0.21%
|
10.05
-16.88%
|
12.09
-11.40%
|
13.65
|
| Work In Process |
|
4.99
+10.92%
|
4.50
+13.93%
|
3.95
-28.81%
|
5.55
|
| Finished Goods |
|
4.35
-19.12%
|
5.38
-16.70%
|
6.46
-34.91%
|
9.93
|
| Prepaid Assets |
|
1.98
-2.80%
|
2.04
+5.38%
|
1.93
-0.67%
|
1.95
|
| Other Current Assets |
|
—
|
—
|
0.00
|
—
|
| Total Non Current Assets |
|
62.17
+204.82%
|
20.39
-55.11%
|
45.44
-1.67%
|
46.21
|
| Net PPE |
|
4.62
+144.24%
|
1.89
-66.70%
|
5.68
-3.99%
|
5.92
|
| Gross PPE |
|
70.62
+6.90%
|
66.07
+0.71%
|
65.61
+3.38%
|
63.46
|
| Accumulated Depreciation |
|
-66.00
-2.85%
|
-64.18
-7.10%
|
-59.92
-4.13%
|
-57.55
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
26.78
+10.37%
|
24.27
-1.68%
|
24.68
+1.43%
|
24.33
|
| Machinery Furniture Equipment |
|
41.03
+5.09%
|
39.04
+2.14%
|
38.22
+4.61%
|
36.54
|
| Leases |
|
2.81
+1.85%
|
2.76
+2.18%
|
2.70
+4.21%
|
2.59
|
| Goodwill And Other Intangible Assets |
|
51.34
+215.57%
|
16.27
-53.87%
|
35.27
-1.98%
|
35.98
|
| Goodwill |
|
13.84
|
0.00
-100.00%
|
12.54
+0.00%
|
12.54
|
| Other Intangible Assets |
|
37.50
+130.51%
|
16.27
-28.43%
|
22.73
-3.04%
|
23.44
|
| Investments And Advances |
|
2.46
|
0.00
|
—
|
—
|
| Non Current Accounts Receivable |
|
—
|
0.04
-57.14%
|
0.08
-44.37%
|
0.15
|
| Non Current Deferred Assets |
|
3.55
+79.90%
|
1.98
-53.18%
|
4.22
+2.85%
|
4.10
|
| Non Current Deferred Taxes Assets |
|
3.55
+79.90%
|
1.98
-53.18%
|
4.22
+2.85%
|
4.10
|
| Other Non Current Assets |
|
0.03
-34.88%
|
0.04
-21.82%
|
0.06
-1.79%
|
0.06
|
| Total Liabilities Net Minority Interest |
|
138.47
+66.06%
|
83.38
-11.56%
|
94.28
-20.92%
|
119.21
|
| Current Liabilities |
|
32.09
+113.47%
|
15.04
-13.29%
|
17.34
-82.75%
|
100.49
|
| Payables And Accrued Expenses |
|
26.84
+107.70%
|
12.92
-14.92%
|
15.19
+2.55%
|
14.81
|
| Payables |
|
13.24
+146.60%
|
5.37
-18.66%
|
6.60
-8.50%
|
7.21
|
| Accounts Payable |
|
6.83
+75.88%
|
3.88
-37.39%
|
6.21
-8.25%
|
6.76
|
| Other Payable |
|
5.38
+573.00%
|
0.80
|
—
|
0.03
|
| Current Accrued Expenses |
|
13.60
+80.05%
|
7.55
-12.03%
|
8.59
+13.03%
|
7.59
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.11
+1.82%
|
0.11
+6.80%
|
0.10
-20.77%
|
0.13
|
| Total Tax Payable |
|
1.02
+49.56%
|
0.68
+72.73%
|
0.40
-5.71%
|
0.42
|
| Income Tax Payable |
|
0.36
+30.47%
|
0.28
+896.43%
|
0.03
+27.27%
|
0.02
|
| Current Debt And Capital Lease Obligation |
|
2.50
+31.04%
|
1.90
+0.95%
|
1.89
-97.79%
|
85.29
|
| Current Debt |
|
0.21
+0.00%
|
0.21
+0.00%
|
0.21
-99.75%
|
83.31
|
| Other Current Borrowings |
|
—
|
—
|
0.21
-99.75%
|
83.31
|
| Current Capital Lease Obligation |
|
2.29
+34.89%
|
1.69
+1.07%
|
1.68
-15.35%
|
1.98
|
| Current Deferred Liabilities |
|
0.20
+294.00%
|
0.05
-56.14%
|
0.11
-45.71%
|
0.21
|
| Current Deferred Revenue |
|
0.20
+294.00%
|
0.05
-56.14%
|
0.11
-19.15%
|
0.14
|
| Total Non Current Liabilities Net Minority Interest |
|
106.38
+55.64%
|
68.35
-11.17%
|
76.94
+310.94%
|
18.72
|
| Long Term Debt And Capital Lease Obligation |
|
98.27
+49.98%
|
65.52
-6.81%
|
70.31
+407.13%
|
13.87
|
| Long Term Debt |
|
87.79
+60.64%
|
54.65
-5.85%
|
58.05
|
—
|
| Long Term Capital Lease Obligation |
|
10.48
-3.63%
|
10.87
-11.37%
|
12.27
-11.53%
|
13.87
|
| Long Term Provisions |
|
0.07
|
—
|
—
|
—
|
| Non Current Deferred Liabilities |
|
4.56
+98.30%
|
2.30
-54.53%
|
5.06
+4.12%
|
4.86
|
| Non Current Deferred Taxes Liabilities |
|
4.56
+98.30%
|
2.30
-54.53%
|
5.06
+4.12%
|
4.86
|
| Other Non Current Liabilities |
|
1.81
|
—
|
—
|
—
|
| Stockholders Equity |
|
-35.18
-46.90%
|
-23.95
-1000.60%
|
-2.18
-582.13%
|
-0.32
|
| Common Stock Equity |
|
-35.18
-46.90%
|
-23.95
-1000.60%
|
-2.18
-582.13%
|
-0.32
|
| Capital Stock |
|
4.19
+112.47%
|
1.97
+0.46%
|
1.96
+61.83%
|
1.21
|
| Common Stock |
|
4.19
+112.47%
|
1.97
+0.46%
|
1.96
+61.83%
|
1.21
|
| Share Issued |
|
371.75
+124.13%
|
165.87
+0.53%
|
164.99
+71.57%
|
96.16
|
| Ordinary Shares Number |
|
359.19
+134.29%
|
153.31
+0.58%
|
152.43
+82.32%
|
83.61
|
| Treasury Shares Number |
|
12.56
+0.00%
|
12.56
+0.00%
|
12.56
+0.00%
|
12.56
|
| Additional Paid In Capital |
|
63.40
+35.99%
|
46.62
+0.35%
|
46.46
+187.01%
|
16.19
|
| Retained Earnings |
|
-79.12
-62.64%
|
-48.64
-82.22%
|
-26.70
-312.56%
|
12.56
|
| Gains Losses Not Affecting Retained Earnings |
|
-5.44
+4.31%
|
-5.68
+0.11%
|
-5.69
-6.22%
|
-5.36
|
| Treasury Stock |
|
24.92
+0.00%
|
24.92
+0.00%
|
24.92
+0.00%
|
24.92
|
| Other Equity Adjustments |
|
0.02
+0.00%
|
0.02
-73.26%
|
0.09
+273.91%
|
0.02
|
| Total Equity Gross Minority Interest |
|
-35.18
-46.90%
|
-23.95
-1000.60%
|
-2.18
-582.13%
|
-0.32
|
| Total Capitalization |
|
52.61
+71.36%
|
30.70
-45.05%
|
55.87
+17614.42%
|
-0.32
|
| Working Capital |
|
9.03
-62.39%
|
24.01
-18.15%
|
29.33
+205.49%
|
-27.80
|
| Invested Capital |
|
52.82
+70.88%
|
30.91
-44.88%
|
56.08
-32.43%
|
82.99
|
| Total Debt |
|
100.76
+49.44%
|
67.43
-6.61%
|
72.20
-27.19%
|
99.16
|
| Net Debt |
|
82.83
+61.88%
|
51.17
-0.98%
|
51.68
-9.97%
|
57.40
|
| Capital Lease Obligations |
|
12.76
+1.56%
|
12.57
-9.88%
|
13.94
-12.00%
|
15.85
|
| Net Tangible Assets |
|
-86.52
-115.13%
|
-40.22
-7.41%
|
-37.45
-3.15%
|
-36.30
|
| Tangible Book Value |
|
-86.52
-115.13%
|
-40.22
-7.41%
|
-37.45
-3.15%
|
-36.30
|
| Current Notes Payable |
|
0.21
+0.00%
|
0.21
+0.00%
|
0.21
|
—
|
| Current Provisions |
|
2.45
+4808.00%
|
0.05
+0.00%
|
0.05
+0.00%
|
0.05
|
| Derivative Product Liabilities |
|
1.66
+215.21%
|
0.53
-66.48%
|
1.57
|
0.00
|
| Financial Assets |
|
0.17
-6.74%
|
0.18
+39.06%
|
0.13
|
0.00
|
| Foreign Currency Translation Adjustments |
|
-5.46
+4.29%
|
-5.71
+1.19%
|
-5.78
-7.36%
|
-5.38
|
| Investmentin Financial Assets |
|
2.46
|
0.00
|
—
|
—
|
| Other Equity Interest |
|
6.71
+0.00%
|
6.71
+0.00%
|
6.71
|
—
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.19
+63.74%
|
-11.56
-1154.83%
|
-0.92
-106.96%
|
13.24
|
| Cash Flow From Continuing Operating Activities |
|
-4.19
+63.74%
|
-11.56
-1154.83%
|
-0.92
-106.96%
|
13.24
|
| Net Income From Continuing Operations |
|
-31.79
-32.35%
|
-24.02
+41.43%
|
-41.01
-4786.74%
|
0.88
|
| Depreciation Amortization Depletion |
|
1.86
+4.95%
|
1.78
-23.83%
|
2.33
-14.98%
|
2.74
|
| Depreciation |
|
0.68
-18.77%
|
0.83
-41.06%
|
1.41
-22.82%
|
1.83
|
| Amortization Cash Flow |
|
1.19
+25.79%
|
0.95
+2.49%
|
0.92
+0.65%
|
0.92
|
| Depreciation And Amortization |
|
1.86
+4.95%
|
1.78
-23.83%
|
2.33
-14.98%
|
2.74
|
| Amortization Of Intangibles |
|
1.19
+25.79%
|
0.95
+2.49%
|
0.92
+0.65%
|
0.92
|
| Other Non Cash Items |
|
11.27
-3.17%
|
11.64
-52.90%
|
24.71
+4336.45%
|
0.56
|
| Stock Based Compensation |
|
1.32
-36.39%
|
2.07
+17.89%
|
1.75
+59.55%
|
1.10
|
| Provisionand Write Offof Assets |
|
0.36
|
0.00
|
0.00
|
—
|
| Asset Impairment Charge |
|
4.09
-57.40%
|
9.61
+64.50%
|
5.84
-15.91%
|
6.94
|
| Deferred Tax |
|
0.49
+923.73%
|
-0.06
+69.27%
|
-0.19
-14.97%
|
-0.17
|
| Deferred Income Tax |
|
0.49
+923.73%
|
-0.06
+69.27%
|
-0.19
-14.97%
|
-0.17
|
| Operating Gains Losses |
|
1.01
+108.09%
|
-12.48
-16764.86%
|
-0.07
+70.63%
|
-0.25
|
| Net Foreign Currency Exchange Gain Loss |
|
1.01
+324.37%
|
0.24
+413.16%
|
-0.08
+69.72%
|
-0.25
|
| Gain Loss On Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.00
+300.00%
|
-0.00
|
| Change In Working Capital |
|
6.19
+1639.30%
|
-0.40
-107.02%
|
5.73
+3430.81%
|
-0.17
|
| Change In Receivables |
|
-2.37
-326.17%
|
1.05
+208.39%
|
-0.97
-115.49%
|
6.24
|
| Change In Inventory |
|
-1.74
-79.40%
|
-0.97
-10.72%
|
-0.88
+80.10%
|
-4.41
|
| Change In Payables And Accrued Expense |
|
8.19
+395.59%
|
-2.77
-1629.83%
|
0.18
+102.38%
|
-7.59
|
| Change In Payable |
|
8.19
+395.59%
|
-2.77
-1629.83%
|
0.18
+102.38%
|
-7.59
|
| Change In Other Working Capital |
|
2.11
-7.77%
|
2.29
-69.00%
|
7.39
+32.24%
|
5.59
|
| Investing Cash Flow |
|
-22.97
-192.78%
|
24.76
+514.19%
|
-5.98
+31.23%
|
-8.69
|
| Cash Flow From Continuing Investing Activities |
|
-22.97
-192.78%
|
24.76
+514.19%
|
-5.98
+31.23%
|
-8.69
|
| Net PPE Purchase And Sale |
|
-0.41
+49.56%
|
-0.80
+27.07%
|
-1.10
+39.24%
|
-1.81
|
| Purchase Of PPE |
|
-0.41
+49.56%
|
-0.80
+27.07%
|
-1.10
+39.24%
|
-1.81
|
| Capital Expenditure |
|
-10.06
-272.19%
|
-2.70
+54.76%
|
-5.98
+31.23%
|
-8.69
|
| Net Investment Purchase And Sale |
|
0.00
+100.00%
|
-0.70
|
0.00
|
0.00
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-0.70
|
0.00
|
0.00
|
| Net Business Purchase And Sale |
|
-12.90
-145.82%
|
28.16
|
0.00
|
0.00
|
| Purchase Of Business |
|
-12.90
|
0.00
|
0.00
|
—
|
| Gain Loss On Sale Of Business |
|
0.00
+100.00%
|
-12.72
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-9.66
-408.10%
|
-1.90
+61.01%
|
-4.88
+29.12%
|
-6.88
|
| Purchase Of Intangibles |
|
-9.66
-408.10%
|
-1.90
+61.01%
|
-4.88
+29.12%
|
-6.88
|
| Financing Cash Flow |
|
28.81
+279.59%
|
-16.04
-30.19%
|
-12.32
-104.72%
|
-6.02
|
| Cash Flow From Continuing Financing Activities |
|
28.81
+279.59%
|
-16.04
-30.19%
|
-12.32
-104.72%
|
-6.02
|
| Net Issuance Payments Of Debt |
|
27.67
+475.58%
|
-7.37
+69.30%
|
-24.00
-1942.47%
|
-1.18
|
| Issuance Of Debt |
|
30.18
+503.52%
|
5.00
-95.00%
|
100.02
+5569.78%
|
1.76
|
| Repayment Of Debt |
|
-2.50
+79.76%
|
-12.37
+90.03%
|
-124.01
-4119.60%
|
-2.94
|
| Long Term Debt Issuance |
|
30.18
+503.52%
|
5.00
-95.00%
|
100.02
+5569.78%
|
1.76
|
| Long Term Debt Payments |
|
-2.50
+79.76%
|
-12.37
+66.83%
|
-37.28
-1168.59%
|
-2.94
|
| Net Long Term Debt Issuance |
|
27.67
+475.58%
|
-7.37
-111.75%
|
62.73
+5438.81%
|
-1.18
|
| Short Term Debt Payments |
|
0.00
|
0.00
+100.00%
|
-86.73
|
0.00
|
| Net Short Term Debt Issuance |
|
0.00
|
0.00
+100.00%
|
-86.73
|
0.00
|
| Net Common Stock Issuance |
|
7.39
|
0.00
-100.00%
|
25.34
|
0.00
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
—
|
-1.05
+81.68%
|
-5.74
-577.24%
|
-0.85
|
| Changes In Cash |
|
1.65
+158.07%
|
-2.84
+85.21%
|
-19.22
-1205.71%
|
-1.47
|
| Effect Of Exchange Rate Changes |
|
-0.17
-297.73%
|
-0.04
+60.71%
|
-0.11
-303.64%
|
0.06
|
| Beginning Cash Position |
|
3.69
-43.89%
|
6.58
-74.61%
|
25.91
-5.19%
|
27.33
|
| End Cash Position |
|
5.17
+39.99%
|
3.69
-43.89%
|
6.58
-74.61%
|
25.91
|
| Free Cash Flow |
|
-14.26
+0.04%
|
-14.26
-106.74%
|
-6.90
-251.70%
|
4.55
|
| Common Stock Issuance |
|
7.39
|
0.00
-100.00%
|
25.34
|
0.00
|
| Interest Paid CFF |
|
-6.25
+17.95%
|
-7.62
+3.71%
|
-7.92
-98.10%
|
-4.00
|
| Interest Paid CFO |
|
—
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Interest Received CFO |
|
0.00
|
0.00
-100.00%
|
0.00
+100.00%
|
0.00
|
| Issuance Of Capital Stock |
|
7.39
|
0.00
-100.00%
|
25.34
|
0.00
|
| Sale Of Business |
|
0.00
-100.00%
|
28.16
|
0.00
|
0.00
|
| Taxes Refund Paid |
|
1.01
+223.72%
|
0.31
+2180.00%
|
-0.01
-100.93%
|
1.62
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|